Business Combinations (Tables)

6 Months Ended

Jun. 30, 2014

Legal Entities [Line Items]

Supplementary Pro Forma Information For Business Combinations

The amounts of revenue and net income of ForwardThink, BioPharm, and Trifecta included in the Company's Condensed Consolidated Statements of Operations (Unaudited) from the applicable acquisition dates to June 30, 2014 are as follows (in thousands):

	Acquisition Dates to June 30, 2014
Revenues	$	17,133
Net income	$	1,700

These unaudited pro-forma results are presented in compliance with the adoption of Accounting Standards Update ("ASU") 2010-29, Business Combinations (Topic 805), Disclosure of Supplementary Pro Forma Information for Business Combinations, and are not necessarily indicative of the actual consolidated results of operations had the acquisitions actually occurred on January 1, 2013 or January 1, 2012 or of future results of operations of the consolidated entities (in thousands, except per share information):

	Six Months Ended June 30,
	2014		2013
Revenues	$	225,012	$	224,147
Net income	$	12,127	$	11,056
Basic net income per share	$	0.37	$	0.34
Diluted net income per share	$	0.36	$	0.33
Shares used in computing basic net income per share		32,629		32,180
Shares used in computing diluted net income per share		33,334		33,390

TriTek [Member]

Legal Entities [Line Items]

Allocation Of The Total Purchase Price Consideration

The Company allocated the total purchase price consideration between tangible assets, identified intangible assets, liabilities, and goodwill as follows (in millions):

Acquired tangible assets	$	11.9
Acquired intangible assets		6.2
Liabilities assumed		(6.1	)
Goodwill		9.1
Total purchase price	$	21.1

ClearTask [Member]

Legal Entities [Line Items]

Allocation Of The Total Purchase Price Consideration

The Company has estimated the allocation of the total purchase price consideration between tangible assets, identified intangible assets, liabilities, and goodwill as follows (in millions):

Acquired tangible assets	$	2.1
Acquired intangible assets		1.6
Liabilities assumed		(0.8	)
Goodwill		5.7
Total purchase price	$	8.6

CoreMatrix [Member]

Legal Entities [Line Items]

Allocation Of The Total Purchase Price Consideration

The Company has estimated the allocation of the total purchase price consideration between tangible assets, identified intangible assets, liabilities, and goodwill as follows (in millions):

Acquired tangible assets	$	4.1
Acquired intangible assets		4.8
Liabilities assumed		(1.6	)
Goodwill		17.1
Total purchase price	$	24.4

ForwardThink [Member]

Legal Entities [Line Items]

Allocation Of The Total Purchase Price Consideration

The Company has estimated the allocation of the total purchase price consideration between tangible assets, identified intangible assets, liabilities, and goodwill as follows (in millions):

Acquired tangible assets	$	4.5
Acquired intangible assets		18.0
Liabilities assumed		(11.6	)
Goodwill		29.1
Total purchase price	$	40.0

BioPharm [Member]

Legal Entities [Line Items]

Allocation Of The Total Purchase Price Consideration

The Company has estimated the allocation of the total purchase price consideration between tangible assets, identified intangible assets, liabilities, and goodwill as follows (in millions):

Acquired tangible assets	$	3.6
Acquired intangible assets		8.4
Liabilities assumed		(1.2	)
Goodwill		5.7
Total purchase price	$	16.5

Trifecta [Member]

Legal Entities [Line Items]

Allocation Of The Total Purchase Price Consideration

The Company has estimated the allocation of the total purchase price consideration between tangible assets, identified intangible assets, liabilities, and goodwill as follows (in millions):

Acquired tangible assets	$	1.8
Acquired intangible assets		5.2
Liabilities assumed		(0.5	)
Goodwill		7.1
Total purchase price	$	13.6